Literature DB >> 3107026

Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant.

A Stenger, J P Couzinier, M Briley.   

Abstract

Midalcipran is a new potential antidepressant selected for its equipotent inhibition of noradrenaline and serotonin uptake and its lack of effect at any postsynaptic receptor. In mice it antagonized the depressant effect of tetrabenazine with an oral ED50 value of 0.5 mg/kg as compared to 2.5 mg/kg for desipramine and 5.1 mg/kg for imipramine. Similar findings were obtained for the inhibition of yohimbine-induced mortality. In the "behavioral despair" test, in mice, immobility was significantly reduced by 10 mg/kg midalcipran whereas 20 mg/kg of desipramine was required for a similar effect. Midalcipran enhanced the behavioral changes induced by 1-tryptophan in the rat and antagonized p-chloramphetamine-induced hyperthermia in mice. In contrast to tricyclic antidepressants, midalcipran showed no anticholinergic, sedative or stimulant properties.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107026     DOI: 10.1007/bf00217054

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  The treatment of depressive states with G 22355 (imipramine hydrochloride).

Authors:  R KUHN
Journal:  Am J Psychiatry       Date:  1958-11       Impact factor: 18.112

2.  Depression.

Authors:  H M van Praag
Journal:  Lancet       Date:  1982-12-04       Impact factor: 79.321

3.  Studies in the mechanism of action of serotonin precursors in depression.

Authors:  H M van Praag
Journal:  Psychopharmacol Bull       Date:  1984

4.  A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine.

Authors:  D T Wong; F P Bymaster; J S Horng; B B Molloy
Journal:  J Pharmacol Exp Ther       Date:  1975-06       Impact factor: 4.030

5.  Pharmacological studies on the antagonism by antidepressants of the hypothermia induced by apomorphine.

Authors:  M K Menon; C A Vivonia; A S Kling
Journal:  Neuropharmacology       Date:  1984-02       Impact factor: 5.250

Review 6.  Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

7.  Antagonism of fenfluramine-induced hyperthermia in rats by some, but not all, selective inhibitors of 5-hydroxytryptamine uptake.

Authors:  M F Sugrue
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

8.  Review of the animal pharmacology and pharmacokinetics of fluvoxamine.

Authors:  V Claassen
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

Review 9.  Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R C Heel; P A Morley; R N Brogden; A A Carmine; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-09       Impact factor: 9.546

10.  Pharmacological studies on serotonin-mediated behaviour.

Authors:  A R Green
Journal:  J Physiol (Paris)       Date:  1981
View more
  10 in total

1.  Information tools for exploratory data analysis in population pharmacokinetics.

Authors:  O Petricoul; L Claret; D Barbolosi; A Iliadis; C Puozzo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

Review 2.  Forced swimming test in mice: a review of antidepressant activity.

Authors:  Benoit Petit-Demouliere; Franck Chenu; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

3.  Stimulation of catecholamine synthesis via activation of p44/42 MAPK in cultured bovine adrenal medullary cells by milnacipran.

Authors:  Koji Shinkai; Yumiko Toyohira; Reiji Yoshimura; Masato Tsutsui; Susume Ueno; Jun Nakamura; Nobuyuki Yanagihara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

4.  Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran.

Authors:  C Palmier; C Puozzo; T Lenehan; M Briley
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.

Authors:  Christian Puozzo; Simone Lens; Christian Reh; Karl Michaelis; Dominique Rosillon; Xavier Deroubaix; Dominique Deprez
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients.

Authors:  M Ansseau; R von Frenckell; C Mertens; J de Wilde; L Botte; J M Devoitille; J L Evrard; A De Nayer; P Darimont; G Dejaiffe
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.

Authors:  Inés Artaiz; Arturo Zazpe; Ana Innerárity; Elena Del Olmo; Alvaro Díaz; José Angel Ruiz-Ortega; Elena Castro; Ruth Pena; Luis Labeaga; Angel Pazos; Aurelio Orjales
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 8.  Milnacipran. A review of its use in depression.

Authors:  C M Spencer; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

9.  Opposite effects of milnacipran, a serotonin norepinephrine reuptake inhibitor, on the levels of nitric oxide and brain-derived neurotrophic factor in mouse brain cortex.

Authors:  Atsuko Ikenouchi-Sugita; Yumiko Toyohira; Reiji Yoshimura; Susumu Ueno; Masato Tsutsui; Jun Nakamura; Nobuyuki Yanagihara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-06       Impact factor: 3.000

10.  In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran.

Authors:  Kazuyoshi Ueta; Takahiro Suzuki; Ichiro Uchida; Takashi Mashimo
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.